Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores

Archives of Cardiovascular Diseases

Volumn 108, Issue 1, 2015, Pages 64-74

  Cohen Solal, Alain ^a,b,c,d   Laribi, Said ^a,c   Ishihara, Shiro ^a,e   Vergaro, Giuseppe ^a,f   Baudet, Mathilde ^c   Logeart, Damien ^a,b,c,d   Mebazaa, Alexandre ^a,b,c,d   Gayat, Etienne ^a,b,c,d   Vodovar, Nicolas ^a   Pascual Figal, Domingo A ^g   Seronde, Marie France ^a,h  

^a University of Paris   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d DHU Fire   (France)

^e STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^f CNR   (Italy)

^g UNIVERSITY OF MURCIA   (Spain)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Acutedecompensated heartfailure; Biomarkers; Natriuretic peptides; Prognosis; Scores

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; GALECTIN 3; INTERLEUKIN 1 RECEPTOR; KIDNEY INJURY MOLECULE 1; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROADRENOMEDULLIN; ST2 PROTEIN; TROPONIN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; CLINICAL FEATURE; COMORBIDITY; CREATININE BLOOD LEVEL; FOLLOW UP; HUMAN; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYMPTOMATOLOGY; UREA NITROGEN BLOOD LEVEL; ACUTE DISEASE; BLOOD; DECISION SUPPORT SYSTEM; HEART FAILURE; PATHOPHYSIOLOGY; TIME;

ACUTE DISEASE; BIOLOGICAL MARKERS; DECISION SUPPORT TECHNIQUES; HEART FAILURE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84920713600     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2014.10.002     Document Type: Review

References (69)

1. Lassus J, Gayat E, Mueller C, et al. Incremental value ofbiomarkers to clinical variables for mortality prediction inacutely decompensated heart failure: the Multinational Obser-vational Cohort on Acute Heart Failure (MOCA) study. Int JCardiol 2013;168:2186-94.
2. Mebazaa A, Nieminen MS, Packer M, et al. Levosimen-dan vs dobutamine for patients with acute decompensatedheart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91.
3. Packer M, Colucci W, Fisher L, et al. Effect of levosi-mendan on the short-term clinical course of patients withacutely decompensated heart failure. JACC: Heart Fail 2013;1:103-11.
4. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombi-nant human relaxin-2, for treatment of acute heart failure(RELAX-AHF): a randomised, placebo-controlled trial. Lancet2013;381:29-39.
5. Bohm M, Link A, Cai D, et al. Beneficial association of beta-blocker therapy on recovery from severe acute heart failuretreatment: data from the Survival of Patients With Acute HeartFailure in Need of Intravenous Inotropic Support trial. Crit CareMed 2011;39:940-4.
6. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, Vasan RS. Eval-uating the added predictive ability of a new marker: from areaunder the ROC curve to reclassification and beyond. Stat Med2008;27:157-72 [discussion 207-12].
7. Fonarow GC, Adams Jr KF, Abraham WT, Yancy CW, BoscardinWJ. Risk stratification for in-hospital mortality in acutelydecompensated heart failure: classification and regression treeanalysis. JAMA 2005;293:572-80.
8. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contem-porary management and one-year mortality in patients withsevere acute heart failure syndromes: The EFICA study. Eur JHeart Fail 2006;8:697-705.
9. Mebazaa A, Parissis J, Porcher R, et al. Short-term survivalby treatment among patients hospitalized with acute heartfailure: the global ALARM-HF registry using propensity scoringmethods. Intensive Care Med 2011;37:290-301.
10. Tavazzi L, Senni M, Metra M, et al. Multicenter prospectiveobservational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on HeartFailure) outcome registry. Circ Heart Fail 2013;6:473-81.
11. Logeart D, Isnard R, Resche-Rigon M, et al. Current aspectsof the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail 2013;15:465-76.
12. Anker SD, Steinborn W, Strassburg S. Cardiac cachexia. Ann Med2004;36:518-29.
13. Pascual-Figal DA, Caballero L, Sanchez-Mas J, Lax A. Progno-stic markers for acute heart failure. Expert Opin Med Diagn2013;7:379-92.
14. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, LopatinM. Admission B-type natriuretic peptide levels and in-hospitalmortality in acute decompensated heart failure. J Am Coll Car-diol 2007;49:1943-50.
15. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-typenatriuretic peptide assay for identifying patients at high riskof re-admission after decompensated heart failure. J Am CollCardiol 2004;43:635-41.
16. Januzzi Jr JL, Camargo CA, Anwaruddin S, et al. The N-terminalPro-BNP investigation of dyspnea in the emergency department(PRIDE) study. Am J Cardiol 2005;95:948-54.
17. Maisel A, Mueller C, Nowak RM, et al. Midregion prohormoneadrenomedullin and prognosis in patients presenting with acutedyspnea: results from the BACH (Biomarkers in Acute HeartFailure) trial. J Am Coll Cardiol 2011;58:1057-67.
18. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside testfor B-type peptide predicts treatment outcomes in patientsadmitted for decompensated heart failure: a pilot study. J AmColl Cardiol 2001;37:386-91.
19. Valle R, Aspromonte N, Milani L, et al. Optimizing fluid man-agement in patients with acute decompensated heart failure(ADHF): the emerging role of combined measurement of bodyhydration status and brain natriuretic peptide (BNP) levels.Heart Fail Rev 2011;16:519-29.
20. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S,Ferreira A. N-terminal-pro-brain natriuretic peptide predictsoutcome after hospital discharge in heart failure patients. Cir-culation 2004;110:2168-74.
21. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS,Mebazaa A. Lowered B-type natriuretic peptide in responseto levosimendan or dobutamine treatment is associated withimproved survival in patients with severe acutely decompen-sated heart failure. J Am Coll Cardiol 2009;53:2343-8.
22. Maisel A. Biomonitoring and biomarker-guided therapy: thenext step in heart failure and biomarker research. J Am CollCardiol 2011;58:1890-2.
23. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guide-lines for the diagnosis and treatment of acute and chronicheart failure 2012: the Task Force for the Diagnosis andTreatment of Acute and Chronic Heart Failure 2012 of the Euro-pean Society of Cardiology. Developed in collaboration withthe Heart Failure Association (HFA) of the ESC. Eur Heart J2012;33:1787-847.
24. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHAguideline for the management of heart failure: executivesummary: a report of the American College of CardiologyFoundation/American Heart Association Task Force on practiceguidelines. Circulation 2013;128:1810-52.
25. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunore-active B-type natriuretic peptide levels and treatment delay inacute decompensated heart failure: an ADHERE (Acute Decom-pensated Heart Failure National Registry) analysis. J Am CollCardiol 2008;52:534-40.
26. Pascual-Figal DA, Casas T, Ordonez-Llanos J, et al. Highly sen-sitive troponin T for risk stratification of acutely destabilizedheart failure. Am Heart J 2012;163:1002-10.
27. Peacock WFt, De Marco T, Fonarow GC, et al. Cardiac tro-ponin and outcome in acute heart failure. N Engl J Med2008;358:2117-26.
28. Perna ER, Macin SM, Cimbaro Canella JP, et al. Minor myocardialdamage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heartfailure. Int J Cardiol 2005;99:253-61.
29. Sakhuja R, Green S, Oestreicher EM, et al. Amino-terminalpro-brain natriuretic peptide, brain natriuretic peptide, andtroponin T for prediction of mortality in acute heart failure.Clin Chem 2007;53:412-20.
30. You JJ, Austin PC, Alter DA, Ko DT, Tu JV. Relation betweencardiac troponin I and mortality in acute decompensated heartfailure. Am Heart J 2007;153:462-70.
31. Arenja N, Reichlin T, Drexler B, et al. Sensitive cardiac troponinin the diagnosis and risk stratification of acute heart failure. JIntern Med 2012;271:598-607.
32. Del Carlo CH, Pereira-Barretto AC, Cassaro-Strunz C, LatorreMdo R, Ramires JA. Serial measure of cardiac troponin T lev-els for prediction of clinical events in decompensated heartfailure. J Card Fail 2004;10:43-8.
33. Metra M, Bettari L, Pagani F, et al. Troponin T levels in patientswith acute heart failure: clinical and prognostic significanceof their detection and release during hospitalisation. Clin ResCardiol 2012;101:663-72.
34. O'Connor CM, Fiuzat M, Lombardi C, et al. Impact of serialtroponin release on outcomes in patients with acute heart fail-ure: analysis from the PROTECT pilot study. Circ Heart Fail2011;4:724-32.
35. Perna ER, Aspromonte N, Cimbaro Canella JP, et al. Minormyocardial damage is a prevalent condition in patients withacute heart failure syndromes and preserved systolic func-tion with long-term prognostic implications: a report fromthe CIAST-HF (Collaborative Italo-Argentinean Study on car-diac Troponin T in Heart Failure) study. J Card Fail 2012;18:822-30.
36. Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes inhigh-sensitive troponin I predict outcome in patients withdecompensated heart failure. Eur J Heart Fail 2011;13:37-42.
37. Potocki M, Breidthardt T, Reichlin T, et al. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides inthe risk stratification of patients with acute dyspnea: an obser-vational study. Crit Care 2009;13:R122.
38. Boyer B, Hart KW, Sperling MI, Lindsell CJ, Collins SP. Biomarkerchanges during acute heart failure treatment. Congest HeartFail 2012;18:91-7.
39. Dieplinger B, Egger M, Koehler W, et al. Prognostic value ofsoluble ST2 in an unselected cohort of patients admitted to anintensive care unit-The Linz Intensive Care Unit (LICU) study.Clin Chim Acta 2012;413:587-93.
40. Januzzi Jr JL, Peacock WF, Maisel AS, et al. Measurement of theinterleukin family member ST2 in patients with acute dyspnea:results from the PRIDE (Pro-Brain Natriuretic Peptide Investi-gation of Dyspnea in the Emergency Department) study. J AmColl Cardiol 2007;50:607-13.
41. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic targetand novel biomarker. Nat Rev Drug Discov 2008;7:827-40.
42. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA,Januzzi JL. Usefulness of soluble concentrations of interleukinfamily member ST2 as predictor of mortality in patients withacutely decompensated heart failure relative to left ventricu-lar ejection fraction. Am J Cardiol 2011;107:259-67.
43. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Solu-ble ST2, high-sensitivity troponin T- and N-terminal pro-B-typenatriuretic peptide: complementary role for risk stratifica-tion in acutely decompensated heart failure. Eur J Heart Fail2011;13:718-25.
44. Rehman SU, Mueller T, Januzzi Jr JL. Characteristics of thenovel interleukin family biomarker ST2 in patients with acuteheart failure. J Am Coll Cardiol 2008;52:1458-65.
45. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR,Januzzi JL. Serum levels of the interleukin-1 receptor familymember ST2, cardiac structure and function, and long-termmortality in patients with acute dyspnea. Circ Heart Fail2009;2:311-9.
46. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3marks activated macrophages in failure-prone hypertrophiedhearts and contributes to cardiac dysfunction. Circulation2004;110:3121-8.
47. van Kimmenade RR, Januzzi Jr JL, Ellinor PT, et al. Utility ofamino-terminal pro-brain natriuretic peptide, galectin-3, andapelin for the evaluation of patients with acute heart failure.J Am Coll Cardiol 2006;48:1217-24.
48. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR,Januzzi JL. Galectin-3, cardiac structure and function, andlong-term mortality in patients with acutely decompensatedheart failure. Eur J Heart Fail 2010;12:826-32.
49. Gullestad L, Ueland T, Kjekshus J, et al. Galectin-3 pre-dicts response to statin therapy in the Controlled RosuvastatinMultinational Trial in Heart Failure (CORONA). Eur Heart J2012;33:2290-6.
50. van der Velde AR, Gullestad L, Ueland T, et al. Prognosticvalue of changes in galectin-3 levels over time in patients withheart failure: data from CORONA and COACH. Circ Heart Fail2013;6:219-26.
51. Campbell CY, Clarke W, Park H, Haq N, Barone BB, Brotman DJ.Usefulness of cystatin C and prognosis following admission foracute heart failure. Am J Cardiol 2009;104:389-92.
52. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatinC in acute heart failure in relation to other markers of renalfunction and NT-proBNP. Eur Heart J 2007;28:1841-7.
53. Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-OtonMD, et al. Complementary prognostic value of cystatin C,N-terminal pro-B-type natriuretic peptide and cardiac tro-ponin T in patients with acute heart failure. Am J Cardiol2009;103:1753-9.
54. Naruse H, Ishii J, Kawai T, et al. Cystatin C in acuteheart failure without advanced renal impairment. Am J Med2009;122:566-73.
55. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serumneutrophil gelatinase-associated lipocalin (NGAL) in predict-ing worsening renal function in acute decompensated heartfailure. J Card Fail 2010;16:49-54.
56. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility ofplasma neutrophil gelatinase-associated lipocalin in patientswith acute heart failure: the NGAL EvaLuation Along withB-type NaTriuretic Peptide in acutely decompensated heartfailure (GALLANT) trial. Eur J Heart Fail 2011;13:846-51.
57. Jungbauer CG, Birner C, Jung B, et al. Kidney injury molecule-1and N-acetyl-beta-D-glucosaminidase in chronic heart failure:possible biomarkers of cardiorenal syndrome. Eur J Heart Fail2011;13:1104-10.
58. Aronson D, Mittleman MA, Burger AJ. Elevated blood ureanitrogen level as a predictor of mortality in patients admit-ted for decompensated heart failure. Am J Med 2004;116:466-73.
59. Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic valueof blood urea nitrogen in patients hospitalized with worseningheart failure: insights from the Acute and Chronic TherapeuticImpact of a Vasopressin Antagonist in Chronic Heart Failure(ACTIV in CHF) study. J Card Fail 2007;13:360-4.
60. van Kimmenade RR, Januzzi Jr JL, Baggish AL, et al. Amino-terminal pro-brain natriuretic peptide, renal function, andoutcomes in acute heart failure: redefining the cardiorenalinteraction? J Am Coll Cardiol 2006;48:1621-7.
61. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnor-malities, clinical profile, and outcome in acute decompensatedheart failure. Eur Heart J 2013;34:742-9.
62. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Fail-ure Model: prediction of survival in heart failure. Circulation2006;113:1424-33.
63. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortalityand morbidity in patients with chronic heart failure. Eur HeartJ 2006;27:65-75.
64. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure:insights from the Organized Program to Initiate Lifesav-ing Treatment in Hospitalized Patients with Heart Failure(OPTIMIZE-HF). J Am Coll Cardiol 2008;52:347-56.
65. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk scorefor in-hospital mortality in patients with heart failure from theAmerican Heart Association get with the guidelines program.Circ Cardiovasc Qual Outcomes 2010;3:25-32.
66. O'Connor CM, Mentz RJ, Cotter G, et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalizedwith acute heart failure and renal dysfunction. Eur J HeartFail 2012;14:605-12.
67. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV.Predicting mortality among patients hospitalized for heartfailure: derivation and validation of a clinical model. JAMA2003;290:2581-7.
68. Felker GM, Leimberger JD, Califf RM, et al. Risk stratificationafter hospitalization for decompensated heart failure. J CardFail 2004;10:460-6.
69. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin oncardiac, renal, and hepatic biomarkers in the Relaxin in AcuteHeart Failure (RELAX-AHF) development program: correlationwith outcomes. J Am Coll Cardiol 2013;61:196-206.